Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Gross Profit: 2014-2025

Historic Gross Profit for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $9.2 million.

  • Aytu Biopharma's Gross Profit fell 23.35% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year decrease of 10.35%. This contributed to the annual value of $45.8 million for FY2025, which is 6.57% down from last year.
  • Per Aytu Biopharma's latest filing, its Gross Profit stood at $9.2 million for Q3 2025, which was down 10.42% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Gross Profit registered a high of $18.6 million during Q2 2023, and its lowest value of -$452,000 during Q1 2021.
  • Moreover, its 3-year median value for Gross Profit was $12.0 million (2024), whereas its average is $12.3 million.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 107.34% in 2021, then soared by 2,906.64% in 2022.
  • Aytu Biopharma's Gross Profit (Quarterly) stood at $12.3 million in 2021, then spiked by 40.60% to $17.3 million in 2022, then fell by 15.56% to $14.6 million in 2023, then decreased by 26.14% to $10.8 million in 2024, then dropped by 23.35% to $9.2 million in 2025.
  • Its Gross Profit was $9.2 million in Q3 2025, compared to $10.3 million in Q2 2025 and $12.8 million in Q1 2025.